ProteoTech
Kirkland
About ProteoTech
ProteoTech, Inc., also known as Proteoglycan Technologies, Inc., operates as a drug development company in the United States. The company offers therapeutics and diagnostics for amyloid diseases. Its products include Exebryl-1, a molecule compound to prevent the formation and accumulation of the soluble and insoluble forms of beta-amyloid protein, as well as amyloid plaques found in Alzheimer's brains of disease victims; PeptiClere, a nasal spray for the treatment of Alzheimer's disease; Synuclere for the treatment of Parkinson's disease; and Systebryl, a small molecule compound for the treatment of systemic amyloidosis associated with type 2 diabetes. ProteoTech, Inc. was founded in 1996 and is headquartered in Kirkland, Washington.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $10.5M
- Last round: Series Unknown (Jun 2011)
- Website: proteotech.com
- Phone: 4258238508
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/proteotech-3242373 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.